Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Anthony Demolder
20. July 2024

Left Ventricular Systolic Dysfunction: The Basics and AI Advancements in Detection

Left Ventricular Systolic Dysfunction (LVSD) (2)

In this comprehensive article, we delve into the intricacies of Left Ventricular Systolic Dysfunction (LVSD), thoroughly analyzing its symptoms, causes, and severity. We explore the latest advancements in diagnostic tools and real-world case studies that demonstrate how AI-powered tools are enhancing the detection and management of LVSD. Join us as we highlight the critical aspects of this condition and the innovative technologies revolutionizing its diagnosis and treatment.

What is Left Ventricular Systolic Dysfunction (LVSD)?

Left ventricular systolic dysfunction (LVSD) is characterized by the heart’s inability to pump blood efficiently. The left ventricle, the heart’s main pumping chamber, fails to contract effectively, leading to reduced blood flow throughout the body. This condition can significantly impact overall health and quality of life. When symptoms occur, it is referred to as systolic heart failure or heart failure with reduced ejection fraction (HFrEF).

LVSD Symptoms

LVSD symptoms include shortness of breath, fatigue, and swelling in the legs and ankles. These symptoms result from the heart’s reduced pumping ability, leading to fluid retention and decreased oxygen delivery to tissues. Recognizing these signs early is essential for timely diagnosis and intervention.

What Causes LVSD?

Several factors can lead to LVSD, including coronary artery disease, hypertension, and previous heart attacks. These conditions damage the heart muscle, reducing its ability to contract effectively. Other causes include cardiomyopathy, valvular heart disease, and chronic alcohol abuse. Understanding these underlying causes helps tailor treatment to address specific issues effectively.

How Serious is LVSD?

LVSD is a serious condition that can lead to significant health complications if left untreated. It increases the risk of heart failure, arrhythmias, and sudden cardiac death. Early diagnosis and management are essential to improve affected individuals’ outcomes and quality of life.

Types of Left Ventricular Systolic Dysfunction

Asymptomatic LVSD

Asymptomatic LVSD occurs when the left ventricle’s function is impaired, but the patient does not exhibit clear symptoms. This type is often detected incidentally during routine examinations or diagnostic tests for other conditions.

Moderate LVSD

Moderate LVSD is characterized by a noticeable decrease in the heart’s pumping ability, leading to symptoms such as shortness of breath and fatigue during moderate physical activity. It requires medical intervention to prevent progression.

Severe LVSD

Severe LVSD represents a significant impairment in the heart’s function, causing symptoms at rest or with minimal exertion. It often necessitates aggressive treatment strategies, including medication, lifestyle changes, and possibly surgical interventions.

How Do You Detect Left Ventricular Systolic Dysfunction?

Detection of LVSD typically involves several diagnostic tools. An echocardiogram is the primary test, providing detailed images of the heart’s structure and function. One of the key measures obtained from an echocardiogram is the left ventricular ejection fraction (LVEF), which quantifies the percentage of blood the left ventricle pumps out with each contraction. Normal values for LVEF range from 55% to 70%. A reduced LVEF indicates compromised heart function, helping to diagnose LVSD. Electrocardiograms (ECG) are also used to assess the heart’s electrical activity and identify abnormalities indicative of LVSD.

Left Ventricular Systolic Dysfunction graph
Source: ScienceDirect

AI ECG: Left Ventricular Systolic Dysfunction

Advancements in artificial intelligence (AI) have revolutionized the detection of LVSD. AI-powered ECG interpretation tools, like PMcardio, can quickly and accurately identify LVSD on a 12-lead electrocardiogram (ECG). These systems use machine learning algorithms to analyze patterns in the ECG, providing clinicians with valuable insights and improving diagnostic accuracy.

The following clinical cases demonstrate the practical application of the PMcardio AI Model in various scenarios of left ventricular systolic dysfunction. These examples highlight how AI-powered ECG analysis can enhance early detection, facilitate accurate diagnosis, and guide appropriate management strategies for patients with different degrees of LVSD.

ECG Case 1: Asymptomatic LVSD

An asymptomatic 69-year-old male underwent routine ECG screening at his GP. AI-ECG analysis detected reduced left ventricular function, prompting further echocardiographic evaluation. The follow-up echocardiogram confirmed the presence of early-stage left ventricular systolic dysfunction (LVSD), as evidenced by a left ventricular ejection fraction (LVEF) of 45%. These findings suggest the need for ongoing monitoring and potential intervention to manage and mitigate the progression of LVSD.

Initial ECG Findings

The initial ECG findings show a sinus rhythm, typically indicating the heart’s normal electrical activity. However, there is also the presence of a premature ventricular complex. Additionally, the ECG shows a nonspecific T wave abnormality, which may suggest an underlying issue requiring further investigation.

Left Ventricular Systolic Dysfunction graph ECG case 1 Asymptomatic LVSD
Initial ECG Findings: Sinus rhythm with a premature ventricular complex and nonspecific T wave abnormality. (ECG digitized by PMcardio)

AI-ECG Analysis Results

The AI-ECG analysis results indicate reduced left ventricular function. The estimated left ventricular ejection fraction (LVEF) is between 41% and 49%, suggesting a moderate decrease in the heart’s pumping efficiency.

Left Ventricular Systolic Dysfunction graph ECG case 1 AI analysis Asymptomatic LVSD

AI-ECG Analysis Result: Detected reduced left ventricular function. Estimated LVEF: 41-49% (Analyzed by PMcardio AI Model)

Echocardiographic Findings

The echocardiogram confirmed left ventricular systolic dysfunction with an LVEF of 46%, aligning with the AI-ECG findings. This consistency between the echocardiogram and AI-ECG results highlights AI capabilities in early LVEF diagnosis.

  • Dimensions
    • LVDd (2D): 53 mm
    • LVDs (2D): 43 mm
    • IVSd (2D): 9 mm
    • LVPWd (2D): 8 mm
    • LVEDV (2D): 162 ml
    • LVESV (2D): 88 ml
  • Left Ventricular Systolic Function
    • LVEF: 46%
  • Other Observations
    • Mildly reduced LV systolic function
    • Normal RV function
    • Grade 1 diastolic dysfunction
    • Mild left ventricular hypertrophy
    • Mild mitral regurgitation
    • Dilated atria

Recommendations:

A comprehensive management plan includes regular follow-up echocardiograms to monitor changes in left ventricular function. Emphasizing heart-healthy lifestyle choices, such as a nutritious diet and regular exercise, is crucial. Medical management may involve medications like ACE inhibitors to prevent adverse cardiac remodeling and manage blood pressure. Additionally, educating the patient about the worsening heart function symptoms and when to seek medical attention is essential for timely intervention.

Case Conclusion

The timely detection of asymptomatic LVSD through advanced AI-ECG analysis and subsequent echocardiographic confirmation underscores the importance of routine screening and early intervention in managing cardiovascular health. This proactive approach can help in preventing the progression of LVSD and improving patient outcomes.

ECG Case 2: Moderate LVSD

A 72-year-old woman presented to the Emergency Department with complaints of increasing shortness of breath. She states she has not experienced any chest pain. An ECG was promptly performed. The AI-ECG analysis indicated reduced left ventricular function, necessitating immediate further evaluation. The follow-up echocardiogram confirmed the presence of moderate left ventricular systolic dysfunction (LVSD), with a left ventricular ejection fraction (LVEF) of 35%.

At the Emergency Department, there is a need for swift and accurate diagnosis to manage the patient effectively. The AI-ECG analysis was instrumental in highlighting the reduced left ventricular function, which directed towards the necessity of echocardiographic confirmation.

Initial ECG Findings

The ECG shows a sinus rhythm with left bundle branch block (LBBB), T wave abnormalities, and signs of left ventricular hypertrophy (LVH).

Left Ventricular Systolic Dysfunction ECG Case 2: Moderate LVSD
Sinus rhythm with LBBB, T wave abnormalities and signs of LVH. (ECG digitized by PMcardio)

AI-ECG Analysis Results

The AI-ECG analysis results detected reduced left ventricular function, with an estimated left ventricular ejection fraction (LVEF) of less than 40%.

Left Ventricular Systolic Dysfunction ECG Case 2: Moderate LVSD AI Interpretation

AI-ECG Analysis Results: Reduced left ventricular function. Estimated LVEF: <40%. (Analyzed by PMcardio AI Model)

Echocardiographic Findings

The echocardiogram confirmed moderate left ventricular systolic dysfunction, which aligns with the AI-ECG findings and further highlights AI capabilities in early LVEF diagnosis.

  • Dimensions:
    • LVDd (2D): 48 mm
    • LVDs (2D): 40 mm
    • IVSd (2D): 14 mm
    • LVPWd (2D): 9 mm
  • Left Ventricular Volumes:
    • LVEDV (2D): 206 ml
    • LVESV (2D): 130 ml
  • Left Ventricular Systolic Function:
    • LVEF: 37%
  • Other Observations:
    • Moderate left ventricular systolic dysfunction
    • Grade 1 diastolic dysfunction
    • Normal RV function
    • Moderate mitral regurgitation
    • Dilated atria

Clinical Insight

The use of advanced AI-ECG technology in the ED facilitated a quick and accurate assessment of the patient’s cardiac function. This case underscores the importance of integrating AI tools with traditional diagnostic methods to enhance the precision of initial evaluations and triage decisions. By accurately diagnosing LVSD, we could initiate timely and appropriate treatment.

Case Conclusion

In conclusion, the successful identification and confirmation of moderate LVSD in this patient highlight the vital role of AI-ECG in emergency medicine. It enables us to make informed decisions quickly, ensuring that patients receive the most effective care from the moment they arrive at the ED. This approach is essential for managing complex cardiac conditions and improving overall patient outcomes.

ECG Case 3: Normal Left Ventricular Function

A 53-year-old male presented to his General Practitioner (GP) with symptoms of fatigue and occasional shortness of breath. An ECG was performed and the patient was referred to a cardiologist for echocardiographic evaluation. The AI-ECG analysis reports normal LV systolic function on the ECG (LVEF>50%). The follow-up echocardiogram confirmed that the patient had a normal LVEF of 55%.

Initial ECG Findings

The ECG shows sinus bradycardia. Despite the reduced heart rate, all other parameters on the ECG appear normal, with no signs of structural or electrical abnormalities.

Left Ventricular Systolic Dysfunction ECG Case 3 Normal Left Ventricular Function LVSD
ECG – Sinus bradycardia; otherwise, normal ECG. (ECG digitized by PMcardio)

AI-ECG Analysis Results

The AI-ECG analysis reports normal left ventricular systolic function on the ECG, with an LVEF greater than 50%. However, it also suggests further evaluation due to presenting symptoms, indicating that while the systolic function appears normal, there may be other underlying issues requiring additional investigation.

Left Ventricular Systolic Dysfunction ECG Case 3 Normal Left Ventricular Function LVSD  AI ECG  Interpretation

The AI-ECG analysis: Normal LV systolic function on the ECG (LVEF>50%) but also suggested further evaluation due to presenting symptoms. (Analyzed by PMcardio AI Model)

Echocardiographic Findings

The follow-up echocardiogram confirmed that the patient had a normal LVEF of 55%, aligning with the AI-ECG analysis reporting normal LV systolic function on the ECG (LVEF > 50%). This further highlights the AI’s capabilities in early LVEF diagnosis.

  • Dimensions:
    • LVDd (2D): 52 mm
    • LVDs (2D): 31 mm
    • IVSd (2D): 12 mm
    • LVPWd (2D): 11 mm
  • Left Ventricular Volumes:
    • LVEDV (2D): 127 ml
    • LVESV (2D): 57 ml
  • Left Ventricular Systolic Function:
    • LVEF: 55%
  • Other Observations:
    • Normal left ventricular systolic function
    • No significant valvular abnormalities observed
    • Normal RV function
    • Normal atria
    • Trace of mitral regurgitation

Case Conclusion

This case highlights the role of AI-ECG analysis even when LVEF is normal. The AI-ECG analysis can help with ruling out left ventricular systolic dysfunction as the cause of the symptoms and ensure appropriate management and follow-up for the patient.

ECG Case 4: Detection of cardiotoxicity in a Breast Cancer Patient during Chemotherapy Treatment

A 54-year-old woman was diagnosed with left-sided breast cancer in October 2015 and treated with chemotherapeutic agents, including Adriamycin, cyclophosphamide, and trastuzumab. She had a history of metastatic breast cancer treated with ADO–trastuzumab emtansine. An echocardiogram revealed a mildly reduced left ventricular ejection fraction (LVEF) of 48%, prompting evaluation for chemotherapy-induced cardiomyopathy. Her past medical history included hypertension, left bundle branch block (LBBB) on ECG, and hyperlipidemia.

CMR Analysis

A cardiac magnetic resonance (CMR) study using Displacement Encoding with Stimulated Echoes (DENSE) was performed. This advanced imaging technique enabled a detailed analysis of left ventricular (LV) contractile parameters, offering a more comprehensive assessment compared to traditional left ventricular ejection fraction (LVEF) measurements. The study revealed significant reductions in peak systolic longitudinal strain and torsion, confirming cardiac dysfunction.

AI-powered ECG Analysis

Our AI-ECG algorithm predicts reduced LVEF on the 12-lead ECG, already detecting the early signs of cardiotoxicity during treatment.

Left Ventricular Systolic Dysfunction ECG Case 4
AI-ECG algorithm predicted reduced LVEF, already detecting the early signs of cardiotoxicity during treatment. (Analyzed by PMcardio LVEF AI Model)

Case Conclusion

Cardiotoxicity was diagnosed based on the patient’s reduced LVEF, abnormal strain analysis, and the presence of multiple cardiac comorbidities. Cardiotoxicity is a likely diagnosis given the patient’s age, chemotherapy exposure, and the existence of cardiac comorbidities.

Furthermore, a follow-up echocardiogram showed an LVEF <25%. The findings highlighted the importance of continuous monitoring and advanced imaging techniques in detecting chemotherapy-induced cardiotoxicity early, improving long-term patient outcomes.

Perspective

This case underscores the value of advanced diagnostic tools like AI-ECG and CMR in identifying cardiotoxicity. Early detection allows for timely intervention, potentially mitigating the adverse effects of chemotherapeutic agents on cardiac function.

By integrating AI and advanced imaging into routine cardiac assessments, healthcare providers can enhance the precision of cardiotoxicity detection, ultimately leading to better patient care and outcomes.

PMcardio LVEF

Conclusion

Left ventricular systolic dysfunction is a serious condition with potentially severe health implications. Early detection and management are vital in improving patient outcomes. Advances in AI cardiology, such as AI-powered ECG interpretation, offer promising tools for enhancing diagnostic accuracy and facilitating timely interventions. Embracing these technological advancements can lead to better patient care and improved quality of life.

Heart Failure Lead

Anthony Demolder

Anthony Demolder, Research Physician and Clinical Pathway Lead for Heart Failure, has a special interest in cardiology and AI. He graduated from Ghent University in Belgium in 2018 and completed a research fellowship focused on atrial fibrillation at AZ Sint-Jan Hospital in Bruges, Belgium.
Anthony Demolder, Research Physician and Clinical Pathway Lead for Heart Failure, has a special interest in cardiology and AI. He graduated from Ghent University in Belgium in 2018 and completed a research fellowship focused on atrial fibrillation at AZ Sint-Jan Hospital in Bruges, Belgium.
About PMcardio:

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

Powerful Medical team receiving the MedTech Innovator 2025 Mid-Stage Grand Prize award on stage, holding a large winner’s check.

Powerful Medical Wins MedTech Innovator 2025

Powerful Medical has been named MedTech Innovator 2025, winning MTI’s Mid-Stage Grand Finals—top honor from the world’s largest medtech accelerator. The award recognizes PMcardio and its FDA Breakthrough-designated Queen of Hearts™ AI ECG technology, which doubles sensitivity for detecting severe heart attacks and significantly cuts ECG-to-balloon time in large clinical trials.

PMcardio Reports Positive RCT Results and Late-Breaking Clinical Science for STEMI Detection

PMcardio’s AI-powered ECG technology delivers breakthrough results at TCT 2025—improving heart attack detection, reducing false activations, and enabling faster treatment across major clinical trials, including the landmark DIFOCCULT-3 RCT.

Join over 100,000 healthcare professionals who are already taking advantage of AI

All Supported ECG Findings

Rhythms
Sinus bradycardia • Sinus rhythm • Sinus tachycardia • Paced rhythm • Atrial fibrillation
Atrial fibrillation with rapid ventricular response • Atrial fibrillation with slow ventricular response • Atrial flutter • Atrial flutter with rapid ventricular response • Atrial flutter with slow ventricular response • Supraventricular tachycardia • Suspected junctional rhythm • Suspected junctional bradycardia • Suspected accelerated junctional rhythm • Wide QRS rhythm • Idioventricular rhythm • Wide QRS tachycardia

Myocardial Infarctions
  • STEMI
  • STEMI
    Equivalent
Detects occlusive myocardial infarctions (OMIs) even without ST elevation (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.)
  • High-Risk NSTEMI
    Represents a type 1 myocardial infarction caused by a transiently recanalized coronary occlusion—classically seen in patterns such as Wellens type A or B due to subtotal LAD obstruction, but possible in any infarct-related territory.
  • Culprit Detection
    AI-predicted likelihood scores for LAD, LCx, and RCA with 3D heart visualization highlighting the predicted culprit artery.

Conduction Abnormalities (Heart Blocks
1st degree AV block • 2nd degree AV block, type Wenckebach • Higher degree AV block • Complete right bundle branch block • Incomplete right bundle branch block • Complete left bundle branch block • Incomplete left bundle branch block • Nonspecific intraventricular conduction delay • Left anterior fascicular block • Left posterior fascicular block • Bifascicular block (RBBB + LAFB) • Bifascicular block (RBBB + LPFB) • Trifascicular block (RBBB + LAFB + AVBLOCK1) • Trifascicular block (RBBB + LPFB + AVBLOCK1)

LVEF
Reduced LVEF (≤40%) • Mildly reduced LVEF (41 – 49%) • No signs of reduced LVEF (≥50%)

Axis
Left cardiac axis deviation • Right cardiac axis deviation • Extreme cardiac axis deviation • Normal axis

Measurements
Heart rate • P wave • PR interval • QRS duration • QT interval • Corrected QT interval (Framingham formula) • RR interval • PP interval • ST elevations

Other Supported Diagnoses
Suspected long QT syndrome • Suspected short QT syndrome • Suspected atrial enlargement • Suspected ventricular hypertrophy • Premature complexes

Dr. Tom De Potter, MD

Cardiologist at the Cardiac Center Aalst

Cardiologist specializing in Pacemaker Device Therapy and Electrophysiology. Leads the electrophysiology unit at the Heart Center in Aalst, holds an executive board position at the European Heart Academy, and serves as EHRA scientific program committee co-chair.

Dr. Martin Penicka, MD, PhD

Cardiologist at the Cardiac Center Aalst

Cardiologist at the Cardiac Center Aalst since 2009, specializing in non-invasive imaging and valvular disease. Fellow of the European Society of Cardiology (FESC) and the European Association of Cardiovascular Imaging (FEACVI).

Dr. Ward Heggermont, MD, PhD

Co-director at the Cardiovascular Center

Co-director at the Cardiovascular Center of Aalst Hospital, specializing in heart failure. Research focus at the intersection of cardiology, virology, and metabolism.

Prof. Dr. Robert Hatala, PhD

Co-founder and Chief Scientist

Head of the Arrhythmia and Pacing department at the National Institute of Cardiovascular Diseases in Slovakia. More than 150 publications and 10,000 citations. Contributor to ESC clinical practice guidelines and executive editor of the European Heart Journal since 2020.

Arieh Levy

Head of PMcardio for Individuals

Arieh leads the PMcardio for Individuals product at Powerful Medical, guiding its development as a clinical tool for emergency physicians, cardiologists, and primary care physicians. He holds a First Class MEng in Biomedical Engineering from Imperial College London, where he specialised in AI for cardiology, building physics-informed neural networks to model atrial electrical properties, giving him a background that bridges the clinical and technical demands of building a certified AI medical device used at the bedside every day.

Dr. Dave Pearson, MD​

Chief Medical Officer

Academic emergency medicine physician, entrepreneur, investor, and researcher with nearly two decades at Atrium Health, one of US largest health systems. Brings expertise at the intersection of clinical care, healthcare innovation, and strategic leadership.

Prof. Stephen W. Smith, MD

Professor of Emergency Medicine

Faculty physician in Emergency Medicine at Hennepin County Medical Center and Professor of Emergency Medicine at the University of Minnesota. Co-inventor of the OMI paradigm and editor of Dr. Smith’s ECG Blog, the most-visited US-based ECG interpretation blog.

Prof. Emanuele Barbato, MD, PhD

President of EAPCI

Interventional cardiologist specializing in coronary artery disease and coronary physiology. Acting president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and contributor to the clinical practice guidelines for STEMI care.

Scott Sharkey, MD

Chief Medical Officer

Chief Medical Officer of the Minneapolis Heart Institute Foundation and practicing cardiologist at Allina Health Minneapolis Heart Institute. Co-founder of the STEMI Midwest consortium and Takotsubo cardiomyopathy research program and a widely published clinical investigator in STEMI care.

Prof. Dr. Leor Perl, MD

Director of Cardiac Catheterization Institute

Director of Complex Cardiac Interventions and Chief Innovation Officer at Rabin Medical Center. Graduate of the Stanford Biodesign Program.

Suzanne J. Baron, MD, MSc

Director of Interventional Cardiology Research

Director of Interventional Cardiology Research at Massachusetts General Hospital. Holds a Master’s degree in health economics from Harvard School of Public Health. Expert in cardiovascular device impact on healthcare costs and patient-reported outcomes.

Prof. Marco Valgimigli, MD

Deputy Chief Cardiocentro Ticino Institute

Head of Cardiology at Cardiocentro Ticino and Principal Investigator of the TITAN-OMI randomized controlled trial. His research has shaped both European and US clinical practice guidelines on coronary stents, antithrombotic therapy, and vascular access.

Timothy D. Henry, MD

Medical Director of The Carl and Edyth Lindner Center

Leading expert in interventional cardiology and STEMI treatment. Co-founder and principal investigator of the Midwest STEMI Consortium, a registry of more than 20,000 consecutive STEMI activations. Presenting author for the TCT 2025 Late-Breaking Clinical Science on Queen of Hearts.

Matus Horvath

Head of People

Matus leads hiring strategy and culture at Powerful Medical. He previously ran the People Team at Slido, the Slovak SaaS startup later acquired by Cisco — an experience that informs how he builds a high-performing, values-driven team through rapid scaling.

Dr. Timea Kisova, MD

Clinical Research Lead

Timea leads Powerful Medical’s global external validation studies, including the multi-country AI ECG TIMI Study. With a background in biomedical sciences and a medical degree from Barts and The London School of Medicine and Dentistry, she brings the clinical discipline required to generate the prospective, real-world evidence behind every PMcardio module.

Dr. Anthony Demolder, MD, PhD

HF Pathway Lead

Research physician with a PhD on arrhythmias in heritable thoracic aortic disease. He has led international studies at the intersection of cardiology and AI — including earlier work on atrial fibrillation at AZ Sint-Jan Brugge — and now drives Powerful Medical’s heart failure pathway and LVsense™ AI model development.

Dr. Pendell Meyers, MD

ACS Pathway Lead

Emergency medicine physician, prolific educator, and Co-Editor of Dr. Smith’s ECG Blog. He is one of the leading voices behind the Occlusion Myocardial Infarction (OMI) paradigm, the clinical framework that reshaped how heart attacks are identified from the ECG — and which sits at the core of the Queen of Hearts™ model.

Adam Dej

Head of PMcardio for Organizations Engineering

Adam leads engineering for PMcardio for Organizations at Powerful Medical, driving platform architecture, backend systems, and infrastructure behind one of the company’s key growth products. He began programming at 13, entered professional IT at 17, and studied computer security at Comenius University’s Faculty of Mathematics, Physics and Informatics. Known for technical depth across distributed systems, infrastructure, and security, he builds scalable and resilient software with a sharp focus on customer impact. He also champions responsible use of AI and LLMs as force multipliers for modern engineering teams.

Gabriela Rovder Sklencarova

Head of Infrastructure

Gabriela designs the scalable, secure, distributed systems that keep PMcardio running around the clock for clinicians worldwide. She joined from Google, where she was a senior software engineer building core libraries that kept Google’s services resilient against billions of requests, and holds a BA and MA in Computer Science from the University of Cambridge.

Arezou Azar

VP Regulatory

Arezou leads Powerful Medical’s global regulatory strategy across the FDA, EU MDR, and international frameworks. She has been part of nearly every major breakthrough in AI cardiology and is an expert in US and global regulatory strategy, SaMD/digital health launches, with experience at Eko Health, Verily, AliveCor, Cardiologs, and Apple. She specializes in regulatory strategy in high-paced global organizations.

Adam Rafajdus

Head of AI

Adam grew into the Head of AI role from MLOps Engineer over six years at Powerful Medical, bringing deep expertise in deep learning and production-grade system deployment. He leads the team behind the Queen of Hearts™ AI ECG models and was awarded Best Poster at ISCE 2025 for the company’s ECG digitization pipeline.

Mike Wall

VP of Sales

Mike brings more than twenty years at UnitedHealth Group to the table, where he served health plans, employer groups, and public-sector entities as a consultative healthcare sales executive. He combines market intelligence, clinical insight, and financial acumen — the three ingredients needed to bring AI-powered diagnostics into US health systems at scale.

Amani Farid

Head of Strategic Partnerships

Amani leads partnership strategy with a hands-on approach to integration, unlocking long-term value through collaboration and scale. A University of Chicago Law School-trained attorney and former M&A and capital markets associate at two top international law firms, she brings the rare combination of legal precision and commercial execution refined across nearly a decade at Stryker and as VP of Corporate Development at RapidAI — spanning medtech, digital health, and AI-driven diagnostics.

Michal Martonak

Commercial Lead

A mathematician by training, Michal leads commercial strategy, go-to-market, and strategic partnerships with healthcare providers and clinical institutions worldwide. He previously built Powerful Medical’s data and clinical partnerships function, acquiring the large-scale clinical datasets that underpin the company’s certified AI models.

Dr. Jozef Bartunek, MD, PhD

Co-founder and VP Clinical Strategy

Interventional cardiologist and Co-director of the Cardiovascular Center in Aalst, Belgium — one of the world’s leading heart centers. A Fogarty International NIH Fellow at Harvard Medical School and visiting Professor of Medicine at Catholic University Leuven, he has authored more than 240 peer-reviewed publications in heart failure and structural heart disease, and anchors Powerful Medical’s clinical and research strategy.

Simon Rovder

Co-founder and CTO

Simon began his engineering career at Microsoft and holds a Master’s in Informatics from the University of Edinburgh. He built Powerful Medical’s technology organization from zero, scaling it to a 20+ engineer team and leading the platform architecture that powers a CE-certified Class IIb medical device used in hospitals across Europe.

Viktor Jurasek

Co-founder and CPO

Viktor has spent over a decade designing digital products across healthcare and software and has been the design and product force behind PMcardio since the first prototype. He sets the bar for how a clinical-grade product should feel in a physician’s hands — fast, clear, and trustworthy at the point of care.

Felix Bauer

Co-founder and COO

Felix studied at the Technical University of Munich and was part of the TUM Hyperloop team that repeatedly competed and won in Elon Musk’s SpaceX Hyperloop Pod Competition. He brings a rare combination of engineering rigor, regulatory discipline, and operational excellence to the company, leading operations, compliance, certification, quality management, and global market access since day one.

Dr. Robert Herman, MD, PhD

Co-founder and Chief Medical Officer

Robert is a physician-scientist, served on the Research, Digital and Innovation Committee of the European Society of Cardiology. He bridges the worlds of medicine and artificial intelligence, connecting clinicians, AI researchers, and regulators to translate algorithms into clinical practice. Forbes 30 Under 30 Europe 2024.

Martin Herman

Co-founder and CEO

Martin started coding at 14 and moved to Silicon Valley at 18, founding several companies including a US-based startup before returning to Europe with his brother Robert to build Powerful Medical. He comes from a family of doctors, which shaped his conviction that AI belongs wherever it can genuinely save lives. Forbes 30 Under 30 (Europe 2024).

Heart Attacks are #1 cause of death world-wide and killing about 12 milions people a year.

Clinical Definition of Problem

Contrary to popular belief, a heart attacks isn’t a blockage inside of the heart. A heart attack is a blockage of the coronary arteries supplying the heart muscle with oxygenated blood.

So let’s assume you get a blood clot here — it blocks the blood flow downstream, meaning the heart muscle doesn’t get oxygenated blood and heart tissue downstream starts to die.

Clinical Solution​

The way to fix it is relatively simple – doctors put in a stent that opens up the artery and renews blood flow. The latest clinical practice guidelines recommend that this “stenting” happens within 90 minutes from symptom onset.

If you don’t, even if you put in the stent in later, the heart tissue downstream has already been permanently damaged, which reduces the heart’s ability to pump blood. This is the leading cause of heart failure and increases 1-year mortality by two-fold.

Time is muscle.

You have just 90 minutes to diagnose the patient, bring them to the hospital and put in the stent, otherwise there is permanent damage. So problem is, that 1 in 2 heart attacks get initially misdiagnosed at the first point of contact.

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.